Viennese Ribbon Biolabs closes 18m Series A financing
Ribbon Biolabs has cashed in 18m in Series A financing led by Hadean Ventures
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1125 entries already.
Entries by Thomas Gabrielczyk
mRNA specalist Ethris raises $26m in Series B financing
/in News/by Thomas GabrielczykGerman mRNA and LNP specialist Ethris GmbH has closed a $26m Series B round led by Laureus Capital.
BioNTech and Pfizer evaluate Omicron-specific vaccine
/in News/by Thomas GabrielczykPfizer Inc and BioNTech SE have started clinical safety testing of an Omikron-specific vaccine in healthy adults 18 through 55 years of age.
Cytovation AS kicks-off with $20m Series A financing
/in News/by Thomas GabrielczykNorways immuno-oncology specialist Cytovation A/S has raised $20m in a Series A financing led by early-stage investor Sandwater.
Valneva vaccine neutralises Omicron variant
/in News/by Thomas GabrielczykFrench-Austrian vaccine specialist Valneva SE has demonstrated that its COVID-19 vaccine induced neutralisation of 87% of the Omicron variant.
Neurimmune expands drug discovery collaboration with Ono Pharmaceutical
/in News/by Thomas GabrielczykSwiss Neurimmune AG has signed an expanded drug discovery collaboration agreement with Ono Pharmaceutical Co., Ltd. covering antibody drug targeting neurodegenerative diseases
Evotec and Lilly to collaborate in metabolic diseases
/in News/by Thomas GabrielczykGerman Evotec SE has entered into a US$1bn drug discovery and development partnership with Eli Lilly and Company in the field of metabolic and renal diseases and diabetes.
Protagen, BioAnalytix and GeneWerk launch ProtaGene
/in News/by Thomas GabrielczykFollowing their last year announcement to merge, Protagen Protein Services GmbH, BioAnalytix, Inc., and GeneWerk GmbH launch a CRO named ProtaGene.
BioNTech SE licences Cresendo Bios Humabody technology
/in News/by Thomas GabrielczykBioNTech and Crescendo Biologics have signed a US-$790m deal to develop multi-specific precision immunotherapies .
Novartis AG executes licence option with Molecular Partners
/in News/by Thomas GabrielczykAfter Molecular Partners AG reported an 78% reduction of hospitalisation by a single ensovibep dose in infected COVID-19 patients, Novartis AG is to pay a CHF150m milestone.